Estimated ulcer-free rate by subgroup at week 48, by Kaplan–Meier method (full analysis set)
| Subgroup | Esomeprazole 20 mg (n=182) | Placebo (n=182) | ||
|---|---|---|---|---|
| n | Ulcer-free rate (95% CI) | n | Ulcer-free rate (95% CI) | |
| Gender | ||||
| Men | 147 | 98.0 (95.2 to 100) | 144 | 84.6 (76.6 to 92.6) |
| Women | 35 | 100 (100 to 100) | 38 | 67.1 (45.1 to 89.1) |
| Age, years | ||||
| ≤64 | 75 | 97.4 (92.5 to 100) | 62 | 75.9 (61.9 to 89.9) |
| 65–74 | 69 | 98.2 (94.7 to 100) | 72 | 88.2 (79.4 to 97.1) |
| ≥75 | 38 | 100 (100 to 100) | 48 | 80.2 (63.6 to 96.8) |
| Helicobacter pylori status | ||||
| Negative | 94 | 100 (100 to 100) | 95 | 84.2 (75.3 to 93.0) |
| Positive | 81 | 96.7 (92.2 to 100) | 82 | 78.4 (65.7 to 91.1) |
| CYP2C19 genotype | ||||
| Homozygous EM | 63 | 100 (100 to 100) | 66 | 83.3 (69.8 to 96.9) |
| Heterozygous EM | 93 | 97.0 (92.7 to 100) | 77 | 83.3 (72.7 to 93.9) |
| PM | 23 | 100 (100 to 100) | 35 | 72.9 (53.9 to 91.8) |
| Low-dose ASA dosage | ||||
| 81 mg | 25 | 100 (100 to 100) | 22 | 71.9 (50.6 to 93.2) |
| 100 mg | 148 | 99.1 (97.5 to 100) | 152 | 83.2 (74.8 to 91.6) |
| >100 mg | 9 | 83.3 (53.5 to 100) | 8 | 83.3 (53.5 to 100) |
| Duration of low-dose ASA intake for prestudy condition | ||||
| <2 weeks | 12 | 100 (100 to 100) | 22 | 0 (0 to 0) |
| 2–4 weeks | 2 | 100 (100 to 100) | 4 | 100 (100 to 100) |
| >4 weeks | 168 | 98.2 (95.7 to 100) | 156 | 83.0 (75.4 to 90.6) |
| Reason for low-dose ASA treatment | ||||
| Primary prevention | 59 | 100 (100 to 100) | 54 | 83.3 (72.1 to 94.6) |
| Secondary prevention | 121 | 97.7 (94.6 to 100) | 126 | 82.8 (74.0 to 91.6) |
| Other | 2 | 100 (100 to 100) | 2 | 0 (0 to 0) |
| Country | ||||
| Japan | 134 | 97.9 (94.8 to 100) | 136 | 84.0 (75.6 to 92.4) |
| Korea | 31 | 100 (100 to 100) | 28 | 42.9 (0 to 100) |
| Taiwan | 17 | 100 (100 to 100) | 18 | 80.0 (58.0 to 100) |
ASA, acetylsalicylic acid; CYP2C19, cytochrome P450 isoenzyme 2C19; EM, extensive metaboliser; PM, poor metaboliser.